Considering that IL−1β and IL−18 were important NLRP3 inflammasome−dependent cytokines, and that the BUR treatment could reduce the release of these two inflammatory mediators, we then explored whether BUR inhibited NLRP3 inflammasome activation in colitis. Here, NLRP3 is linked to colitis.